32114 Federal Register / Vol. 65, No. 99 / Monday, May 22, 2000 / Notices

a total of 90 days to submit data,

analyses, and other relevant

information.

Although the agency has reviewed the

requests asking for extensions of the

comment period, the longest of which is

for an additional 1 year, FDA does not

believe that such a lengthy delay is in

the best interest of the public health.

FDA believes that delaying the receipt

of comments for more than an

additional 45 days (for a total of 90

days) is too long given the public health

concerns at issue.

II. How to Submit Comments

Interested persons may, on or before

July 3, 2000, submit written comments

to the Dockets Management Branch

(address above). You may also send

comments to the Dockets Management

Branch via e-mail to

‘‘FDADockets@oc.fda.gov’’. You should

annotate and organize your comments to

identify the specific issues to which

they refer. You must submit two copies

of comments, identified with the docket

number found in brackets in the

heading of this document, except that

you may submit one copy if you are an

individual. You may review received

comments in the Dockets Management

Branch between 9 a.m. and 4 p.m.,

Monday through Friday.

Dated: May 16, 2000.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy.

[FR Doc. 00–12749 Filed 5–19–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee;

Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Blood Products

Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on June 15, 2000, from 8 a.m. to 5

p.m. and on June 16, 2000, from 9 a.m.

to 12:30 p.m.

Location: Holiday Inn, 8777 Georgia

Ave., Silver Spring, MD.

Contact Person: Linda A. Smallwood,

Center for Biologics Evaluation and

Research (HFM–302), Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448, 301–827–

3514, or FDA Advisory Committee

Information Line, 1–800–741–8138

(301–443–0572 in the Washington, DC

area), code 19516. Please call the

Information Line for up-to-date

information on this meeting.

Agenda: On June 15, 2000, the

committee will hear updates on

summaries of the Public Health Service

Advisory Committee on Blood Safety

and Availability meeting, April 25 and

26, 2000; FDA’s Transmissible

Spongiform Encephalopathies Advisory

Committee meeting, June 1 and 2, 2000;

the FDA-sponsored workshop on

plasticizers, October 18, 1999; and a

briefing on blood supply monitoring.

The committee will also hear

presentations and provide

recommendations on plasma pool

screening by nucleic acid tests for

Hepatitis A virus and, in the afternoon,

the committee will hear presentations

and provide recommendations on the

development of rapid human

immunodeficiency virus (HIV) tests. On

June 16, 2000, the committee will hear

updates on the requirements for syphilis

testing, the risk of Hepatitis C virus to

sexual partners, and relative sensitivity

of Hepatitis B surface antigen and

Hepatitis B virus nucleic acid tests.

Also, the committee will hear and

discuss presentations on the proposed

document entitled ‘‘FDA Guidance on

Universal Leukoreduction: Current

Thinking.’’

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by Friday, June 2, 2000. Oral

presentations from the public will be

scheduled between approximately 11

a.m. to 11:30 a.m. and 2:30 p.m. to 3:30

p.m. on June 15, 2000, and between

approximately 10:30 a.m. to 11:30 a.m.

on June 16, 2000. Time allotted for each

presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before Friday, June 9, 2000, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

requested to make their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 11, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–12747 Filed 5–19–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

Periodically, the Health Resources

and Services Administration (HRSA)

publishes abstracts of information

collection requests under review by the

Office of Management and Budget, in

compliance with the Paperwork

Reduction Act of 1995 (44 U.S.C.

Chapter 35). To request a copy of the

clearance requests submitted to OMB for

review, call the HRSA Reports

Clearance Office on (301)–443–1129.

The following request has been

submitted to the Office of Management

and Budget for review under the

Paperwork Reduction Act of 1995:

Proposed Project: The Black Lung

Clinic Program Guidelines (42 CFR 55a)

(OMB No. 0915–0081) Extension

The purpose of the Black Lung Clinics

Program (BLCP) is to stimulate and

encourage local public and private

agencies to improve the health status of

coal workers and to increase

coordination with other programs to

assist the coal worker population. The

goal of the BLCP is to provide services

to minimize the effects of respiratory

and pulmonary impairments of coal

miners. Grantees provide specific

diagnostic and treatment procedures

required in the management of problems

associated with black lung disease

which improve the functional status,

i.e., ‘‘quality of life’’, of the miner and

reduces economic costs associated with

morbidity and mortality arising from

pulmonary diseases.

This request is for approval of the

application requirements which are

included in the program guidelines and

the program regulation (42 CFR 55a.201

and 55a.301). Grantees must submit

applications annually for continued

grant support. The regulations outline

the requirements for grant applications

for States (55a.201) and entities other

than States (55a.301). The program

guidelines further elaborate on these

requirements.

The grant application form is cleared

under another OMB approval (OMB No.